Ozmosi | Iodofalan Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Iodofalan

Alternative Names: Iodofalan, 131I-IPA, 18F-FET, TLX101, TLX-101
Clinical Status: Active
Latest Update: 2025-08-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: Fast Track -
Priority Review - Brain Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Telix Pharm
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Iodofalan

Countries in Clinic: Australia

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Brain Cancer|Glioblastoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12625000934448

ACTRN12625000934448

P3

Not yet recruiting

Glioblastoma|Brain Cancer

2027-07-30

2025-08-31

Treatments

NCT07100730

IPAX BrIGHT

P3

Not yet recruiting

Glioblastoma

2027-07-01

2025-08-05

Primary Endpoints|Treatments